These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

137 related items for PubMed ID: 9481883

  • 1. Fenfluramine challenge test in obsessive-compulsive disorder--first results.
    Pidrman V, Tůma I.
    Acta Medica (Hradec Kralove); 1997; 40(4):99-102. PubMed ID: 9481883
    [Abstract] [Full Text] [Related]

  • 2. Plasma prolactin response to d-fenfluramine in obsessive-compulsive patients before and after fluvoxamine treatment.
    Monteleone P, Catapano F, Bortolotti F, Maj M.
    Biol Psychiatry; 1997 Aug 01; 42(3):175-80. PubMed ID: 9232209
    [Abstract] [Full Text] [Related]

  • 3. Prolactin response to d-fenfluramine in obsessive-compulsive patients, and outcome of fluvoxamine treatment.
    Monteleone P, Catapano F, Di Martino S, Ferraro C, Maj M.
    Br J Psychiatry; 1997 Jun 01; 170():554-7. PubMed ID: 9330023
    [Abstract] [Full Text] [Related]

  • 4. A review of the efficacy of selective serotonin reuptake inhibitors in obsessive-compulsive disorder.
    Pigott TA, Seay SM.
    J Clin Psychiatry; 1999 Feb 01; 60(2):101-6. PubMed ID: 10084636
    [Abstract] [Full Text] [Related]

  • 5. Citalopram for treatment-resistant obsessive-compulsive disorder.
    Pallanti S, Quercioli L, Paiva RS, Koran LM.
    Eur Psychiatry; 1999 Apr 01; 14(2):101-6. PubMed ID: 10572334
    [Abstract] [Full Text] [Related]

  • 6. Neuroendocrine and behavioral responses to challenge with the indirect serotonin agonist dl-fenfluramine in adults with obsessive-compulsive disorder.
    McBride PA, DeMeo MD, Sweeney JA, Halper J, Mann JJ, Shear MK.
    Biol Psychiatry; 1992 Jan 01; 31(1):19-34. PubMed ID: 1311964
    [Abstract] [Full Text] [Related]

  • 7. [Treatment of resistant depression with the citalopram-lithium combination. Methodology of a double-blind multicenter study and preliminary results].
    Souche A, Montaldi S, Uehlinger C, Kasas A, Reymond MJ, Reymond P, Baumann P, Dufour H.
    Encephale; 1991 Jan 01; 17(3):213-9. PubMed ID: 1864255
    [Abstract] [Full Text] [Related]

  • 8. A double blind comparison of venlafaxine and paroxetine in obsessive-compulsive disorder.
    Denys D, van der Wee N, van Megen HJ, Westenberg HG.
    J Clin Psychopharmacol; 2003 Dec 01; 23(6):568-75. PubMed ID: 14624187
    [Abstract] [Full Text] [Related]

  • 9. Prolactin in childhood obsessive-compulsive disorder: clinical correlates and response to clomipramine.
    Hanna GL, McCracken JT, Cantwell DP.
    J Am Acad Child Adolesc Psychiatry; 1991 Mar 01; 30(2):173-8. PubMed ID: 2016218
    [Abstract] [Full Text] [Related]

  • 10. Efficacy of drug treatment in obsessive-compulsive disorder. A meta-analytic review.
    Piccinelli M, Pini S, Bellantuono C, Wilkinson G.
    Br J Psychiatry; 1995 Apr 01; 166(4):424-43. PubMed ID: 7795913
    [Abstract] [Full Text] [Related]

  • 11. Fenfluramine stimulation of prolactin in obsessive-compulsive disorder.
    Hewlett WA, Vinogradov S, Martin K, Berman S, Csernansky JG.
    Psychiatry Res; 1992 Apr 01; 42(1):81-92. PubMed ID: 1603884
    [Abstract] [Full Text] [Related]

  • 12. Fenfluramine augmentation of serotonin reuptake blockade antiobsessional treatment.
    Hollander E, DeCaria CM, Schneier FR, Schneier HA, Liebowitz MR, Klein DF.
    J Clin Psychiatry; 1990 Mar 01; 51(3):119-23. PubMed ID: 2106515
    [Abstract] [Full Text] [Related]

  • 13. Paroxetine versus clomipramine in the treatment of obsessive-compulsive disorder. OCD Paroxetine Study Investigators.
    Zohar J, Judge R.
    Br J Psychiatry; 1996 Oct 01; 169(4):468-74. PubMed ID: 8894198
    [Abstract] [Full Text] [Related]

  • 14. Effectiveness of long-term augmentation with citalopram to clomipramine in treatment-resistant OCD patients.
    Marazziti D, Golia F, Consoli G, Presta S, Pfanner C, Carlini M, Mungai F, Catena Dell'osso M.
    CNS Spectr; 2008 Nov 01; 13(11):971-6. PubMed ID: 19037176
    [Abstract] [Full Text] [Related]

  • 15. Escitalopram in the treatment of patients with schizophrenia and obsessive-compulsive disorder: an open-label, prospective study.
    Stryjer R, Dambinsky Y, Timinsky I, Green T, Kotler M, Weizman A, Spivak B.
    Int Clin Psychopharmacol; 2013 Mar 01; 28(2):96-8. PubMed ID: 23211492
    [Abstract] [Full Text] [Related]

  • 16. Citalopram in the treatment of obsessive-compulsive disorder: an open pilot study.
    Koponen H, Lepola U, Leinonen E, Jokinen R, Penttinen J, Turtonen J.
    Acta Psychiatr Scand; 1997 Nov 01; 96(5):343-6. PubMed ID: 9395151
    [Abstract] [Full Text] [Related]

  • 17. Agomelatine augmentation in obsessive compulsive disorder: a preliminary report.
    Tzavellas E, Karaiskos D, Ilias I, Liappas I, Paparrigopoulos T.
    Psychiatriki; 2014 Nov 01; 25(3):179-84. PubMed ID: 25367661
    [Abstract] [Full Text] [Related]

  • 18. Use of factor-analyzed symptom dimensions to predict outcome with serotonin reuptake inhibitors and placebo in the treatment of obsessive-compulsive disorder.
    Mataix-Cols D, Rauch SL, Manzo PA, Jenike MA, Baer L.
    Am J Psychiatry; 1999 Sep 01; 156(9):1409-16. PubMed ID: 10484953
    [Abstract] [Full Text] [Related]

  • 19. Changes in platelet markers of obsessive-compulsive patients during a double-blind trial of fluvoxamine versus clomipramine.
    Marazziti D, Pfanner C, Palego L, Gemignani A, Milanfranchi A, Ravagli S, Lensi P, Presta S, Cassano GB.
    Pharmacopsychiatry; 1997 Nov 01; 30(6):245-9. PubMed ID: 9442546
    [Abstract] [Full Text] [Related]

  • 20. Plasma oxytocin changes and anti-obsessive response during serotonin reuptake inhibitor treatment: a placebo controlled study.
    Humble MB, Uvnäs-Moberg K, Engström I, Bejerot S.
    BMC Psychiatry; 2013 Dec 23; 13():344. PubMed ID: 24359174
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.